A novel approach to IL‑15/IL‑2 pathway modulation
ANB033 targets the shared beta subunit of two key cytokine receptors, offering a dual-pathway approach to reducing pathogenic inflammation by multiple immune cells in autoimmune disease.
ANB033 is a novel anti‑CD122 antagonist that targets the shared beta subunit of the IL‑15 and IL‑2 receptors.
- These cytokines drive the proliferation and survival of key immune cell subsets, including CD8+ and CD4+ T cells, NK cells and ILC2s, that play central roles in autoimmune and inflammatory diseases
- By modulating this pathway, ANB033 has the potential to reduce inflammation and help maintain remission
ANB033 has pipeline-in-a-product potential and is currently in a Phase 1b trial for both celiac disease and eosinophilic esophagitis.
Paul working in the First Tracks Lab
Why target CD122?
- CD122 is the shared receptor subunit through which both IL‑15 and IL‑2 signal
- IL‑15 and IL‑2 are central cytokines in pathogenic inflammation across a broad range of inflammatory diseases
How ANB033 works
- ANB033 blocks CD122 to inhibit pathogenic immune cells
- CD122 — the IL‑2Rβ subunit — forms part of the IL‑15 and IL‑2 receptor complexes expressed on subsets of CD8+ and CD4+ T cells and NK cells
- Blocking CD122 reduces immune cell subsets that rely on IL‑15 and/or IL‑2 for proliferation and survival
- CD122-expressing cells are overrepresented in targeted diseases
- Celiac disease: intraepithelial lymphocytes, including cytotoxic CD8+ and NK cells
- Eosinophilic esophagitis: ILC2s
Scientific presentations & publications
Access the latest data, abstracts and peer-reviewed literature about ANB033